Aethlon Medical (NASDAQ:AEMD) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research note issued to investors on Wednesday morning. The firm issued a sell rating on the medical equipment provider’s stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of Aethlon Medical in a research note on Monday, March 10th.

Aethlon Medical Trading Down 11.6 %

Shares of AEMD opened at $0.37 on Wednesday. The firm has a market cap of $5.40 million, a PE ratio of -0.24 and a beta of 1.80. The firm has a fifty day simple moving average of $0.62 and a two-hundred day simple moving average of $0.50. Aethlon Medical has a 1-year low of $0.24 and a 1-year high of $1.85.

Aethlon Medical (NASDAQ:AEMD) last announced its earnings results on Wednesday, February 12th. The medical equipment provider reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.09. As a group, research analysts forecast that Aethlon Medical will post -0.73 EPS for the current fiscal year.

Institutional Investors Weigh In On Aethlon Medical

Hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC bought a new stake in shares of Aethlon Medical during the 4th quarter valued at $25,000. Allegiance Financial Group Advisory Services LLC bought a new stake in shares of Aethlon Medical during the 4th quarter valued at $26,000. Sassicaia Capital Advisers LLC bought a new stake in shares of Aethlon Medical during the 4th quarter valued at $31,000. Virtu Financial LLC bought a new stake in shares of Aethlon Medical during the 4th quarter valued at $81,000. Finally, Boothbay Fund Management LLC bought a new position in Aethlon Medical in the 4th quarter worth $186,000. Institutional investors own 1.99% of the company’s stock.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.